Leadership & Faculty


  • Richard Weinshilboum, M.D.

    Richard Weinshilboum, M.D.

    • Co-Director, Pharmacogenomics Program
    • Mary Lou and John H. Dasburg Professor of Cancer Genomics

    What excites you about individualized medicine?

    "This is an amazing time that I wasn't sure I would see during my career. We're making the transition from knowing one 'sketch' of the human genome — that's the Human Genome Project — to being able to know the individual genome for each of our patients and their tumors."

  • Jolene M. Summer Bolster

    Jolene M. Summer Bolster

    • Associate Administrator

    What excites you about individualized medicine?

    "I've had the great fortune of seeing individualized medicine in action through pharmacogenomics testing, targeted therapy, predictive genomics; and the impact of a definitive diagnosis for a family seeking answers. I'm excited to have the privilege of leading this amazing team of clinician, scientific and administrative experts who are translating individualized medicine discoveries into clinical practice for our patients. The energy and commitment the teams bring each day continues to inspire me and generates enthusiasm for what is yet to come."

  • Konstantinos N. Lazaridis, M.D.

    Konstantinos N. Lazaridis, M.D.

    • Everett J. and Jane M. Hauck Associate Director in Minnesota
    • William O. Lund, Jr., and Natalie C. Lund Director, Clinomics Program

    What will medicine look like in the future?

    "In the next five to 10 years, the use of next-generation sequencing for diagnosis, prognosis and therapy will be as common as ordering a complete blood count, a chest X-ray or a urinalysis."

  • Aleksandar Sekulic, M.D., Ph.D.

    Aleksandar Sekulic, M.D., Ph.D.

    • Assistant Director in Arizona

    What will individualized medicine mean for the patient?

    "As physicians we always strive to provide the best possible care for the patient in front of us. Individualized medicine builds on this legacy and, by incorporating the cutting-edge molecular advances, enables us to provide personalized care with much greater precision."

  • Sanjay P. Bagaria, M.D.

    Sanjay P. Bagaria, M.D.

    • Associate Director in Florida

    What excites you about individualized medicine?

    "This is a very exciting time. We have reached a point where technology allows us to explore the causes of and treatments for human disease like never before. We are applying these new technologies to ensure that Mayo Clinic continues its long tradition of providing the best care for each and every patient."

  • Asher A. Chanan-Khan, M.D.

    Asher A. Chanan-Khan, M.D.

    • Assistant Director in Florida

    What does the future hold?

    "Hematological malignancies have proven to be some of the most difficult cancers, with tragically low survival rates for many. Our hope is that knowing the genomic components of these cancers and tailoring treatments to the molecular changes will not only help our patients live longer but also allow us to prevent them before they become a problem."

Translational programs

  • John C. Cheville, M.D.

    John C. Cheville, M.D.

    • Co-Director, Biomarker Discovery Program

    What does the future hold?

    "In the case of prostate cancer, understanding the individual genetic changes in each prostate cancer in the context of the pathologic features, and planning treatment around these findings, is a new paradigm in caring for men with prostate cancer."

  • George Vasmatzis, Ph.D.

    George Vasmatzis, Ph.D.

    • Co-Director, Biomarker Discovery Program

    What will be the impact of individualized medicine?

    "Genome sequencing is the single most important invention of our lifetime. It will eventually turn out to be more important than the microprocessor and personal computer — and that's coming from an electrical engineer."

  • Eric D. Wieben, Ph.D.

    Eric D. Wieben, Ph.D.

    • Director, Medical Genome Facility
    • Co-Director, Clinomics Program

    What excites you about individualized medicine?

    "The idea that a single change in the 6 billion letters of a person's DNA could cause a disease or make someone sick fascinated me when I started graduate school. What we're able to do now with next-generation sequencing makes it all the more interesting because we can look at all 6 billion letters in a single assay. Now, we can begin to unravel the complexities of the most frustrating diseases and have a real impact on the health and well-being of our patients."

  • Tamas Ordog, M.D.

    Tamas Ordog, M.D.

    • Director, Epigenomics Program

    What does the future hold?

    "Genomics tells us what is hard-wired in our bodies. Epigenomics allows us to manipulate the control systems. We're working toward a time when genes can simply be turned on or off, like a light switch, to restore health in an individual patient."

  • Grzegorz S. Nowakowski, M.D.

    Grzegorz S. Nowakowski, M.D.

    • Associate Director, Epigenomics Program

    What will individualized medicine mean for the patient?

    "New genomic sequencing techniques give us the unprecedented ability to understand what’s happening within the individual cancer cells of every cancer patient. This represents a major shift in our approach to cancer treatment − moving away from a best-for-most model to what’s optimally beneficial for each individual patient."

  • Nicholas Chia, Ph.D.

    Nicholas Chia, Ph.D.

    • Associate Director, Microbiome Program

    What excites you about individualized medicine?

    "Genomics is unequivocally the most powerful tool in microbiology and microbiologists have always been at the forefront in utilizing genomics technologies. Without genetic sequencing, we would have continued to be unable to assess the evolutionary relationships and diversity of life."

  • Purna C. Kashyap, M.B.B.S.

    Purna C. Kashyap, M.B.B.S.

    • Associate Director, Microbiome Program

    What is important about your role in individualized medicine?

    "We have been pleasantly surprised by the discoveries over the past decade on the role of the microbiome in shaping human health. As a physician-scientist, my goal is to ensure that we stay at the forefront in the development of novel treatments and that we offer our patients access to the latest microbiome-targeted therapies."

  • Liewei Wang, M.D., Ph.D.

    Liewei Wang, M.D., Ph.D.

    • Director, Pharmacogenomics Program

    What does the future hold?

    "Individualized medicine will allow physicians to diagnose, treat and prevent disease uniquely for each patient. This process will lead to better clinical outcomes."

Infrastructure programs

  • Richard Sharp, Ph.D.

    Richard Sharp, Ph.D.

    • Director, Bioethics Program

    Why is Mayo Clinic able to excel in individualized medicine?

    "Mayo is uniquely positioned to shape the future of individualized medicine in large part because of our traditional focus on meeting the needs of each individual patient. Our new programs in individualized medicine and biomedical ethics are natural extensions of that guiding philosophy. We see each patient's medical needs within the larger context of their personal life circumstances, goals, and values."

  • Jean-Pierre A. Kocher, Ph.D.

    Jean-Pierre A. Kocher, Ph.D.

    • Director, Bioinformatics Program

    What excites you about individualized medicine?

    "All of us in bioinformatics at Mayo Clinic are excited about looking at genome data and discovering new variants and thinking about all the ways this new information is going to help create a new test or improve the way a patient is cared for."

  • Eric W. Klee, Ph.D.

    Eric W. Klee, Ph.D.

    • Associate Director, Bioinformatics Program

    What does the future hold?

    "I believe the future of medicine will see an increasing role of genetics to individualize patient treatments and increase the application of preventive medicine practice. In the coming years, our understanding of genomic and epigenetic data will continue to improve at an amazing rate, allowing previously fictitious ideas of medicine to become realities."

  • Stephen N. Thibodeau, Ph.D.

    Stephen N. Thibodeau, Ph.D.

    • David F. and Margaret T. Grohne Director, Biorepositories Program
    • William H. Donner Professor

    Why is Mayo Clinic able to excel in individualized medicine?

    "Access to high-quality, clinically annotated biospecimens is an essential ingredient for individualized medicine. The availability of biospecimens and clinical information from large numbers of healthy individuals and from patients with a variety of diseases dramatically accelerates our ability to translate genomic research into clinical practice. With these resources, the range of diseases we are able to study and the pace of discovery is staggering."

  • James D. Buntrock

    James D. Buntrock

    • Director, Information Technology Program

    Why did you choose genomics?

    "Technology is so engrained in our daily lives that we rarely stop to think how it can be used. Genomics will eventually become as much a part of us as computers and smartphones."

  • Timothy B. Curry, M.D., Ph.D.

    Timothy B. Curry, M.D., Ph.D.

    • Director, Education Program

    What is important about your role in individualized medicine?

    "Education is crucial in translating individualized medicine into everyday practice. From the lecture hall to the hospital room, we are using innovative approaches to meet the unique educational needs of learners, whether they are patients, providers, researchers or students."

  • Alan H. Bryce, M.D.

    Alan H. Bryce, M.D.

    • Associate Director, Education Program in Arizona

    What excites you about individualized medicine?

    "In my practice, I have been able to witness first-hand the impact individualized medicine has in prevention, diagnosis and treatment of cancer. The application and impact of precision medicine has expanded into other disciplines, beyond oncology, and that is truly exciting. I am thrilled to be a part of education leadership for this area of medicine, as physician and patient knowledge plays an integral role in closing gaps in understanding the value of genomics in patient care."

  • William C. Palmer, M.D.

    William C. Palmer, M.D.

    • Associate Director, Education Program in Arizona

    Why is Mayo Clinic able to excel in individualized medicine?

    "Mayo Clinic's multidisciplinary group practice is ideally positioned to lead the field of individualized medicine, though enterprise-wide collaboration in research, education and patient care. Translating genomic applications such as pharmacogenomics and cutting-edge precision diagnostics from the research lab to the patients we treat remains our primary goal. Innovatively educating both providers and patients keeps Mayo at the forefront of this ever-changing field."